Regenerative Therapies Library
Every article, presentation, spotlight, and news item we've tagged to Regenerative Therapies.
Showing 169–192 of 310
Blocking telomere alarms restores blood production in aging
Blocking the DNA damage response at telomeres restores blood cell production and reduces senescence in aged mice, suggesting a pharmacological approach to counteract hematopoietic dysfunction driven by telomere shortening. This targets a fundamental mechanism of aging rather than its downstream effects.
Niagen Bioscience launches Niagen Plus telehealth platform
Niagen Bioscience launched Niagen Plus, a telehealth platform delivering prescription-only nicotinamide riboside (Niagen) via at-home subcutaneous injection. The injectable route is positioned to bypass first-pass hepatic metabolism and improve tissue bioavailability compared to oral administration.
Fisetin Reverses Chemotherapy-Induced Vascular Aging
Fisetin, a naturally occurring senolytic compound, reversed vascular dysfunction and aortic stiffening induced by doxorubicin in mice by suppressing senescent cells and their inflammatory secretions, restoring nitric oxide availability. This demonstrates a pharmacological pathway to counter drug-induced premature vascular aging.
Advancing senescence translation through the Senotherapeutics Biomarker Consortium
The Senotherapeutics Biomarker Consortium establishes standardized biomarkers for identifying and measuring cellular senescence across tissues and populations, enabling translation of senolytic therapies from research to clinical practice. This addresses a critical gap in longevity medicine: the ability to reliably detect senescent cells and track treatment response in living humans.
Senolytic Treatment Reduces Acute and Chronic Lung Inflammation in an Aged Mouse Model of Influenza
Senolytic treatment with ABT-263 reduced lung and intestinal inflammation and prevented long-term pulmonary damage in aged mice infected with influenza, though it did not reduce viral replication itself. The findings indicate that pre-existing senescent cells drive inflammatory pathology rather than viral control, suggesting a therapeutic target for improving outcomes in older adults.
DNA Methylation Signatures of Cellular Senescence Are Not Reversed by Senolytic Treatment
Senolytic treatments did not reverse epigenetic signatures associated with cellular senescence, despite reducing senescent cell burden. This finding questions whether DNA methylation changes adequately capture senescence biology and whether current aging biomarkers respond as expected to geroscience interventions.
A Popular Senolytic Treatment Causes Brain Damage in Mice
Dasatinib and quercetin (D+Q), a widely used senolytic combination, impairs oligodendrocyte function and reduces myelination in the brain through endoplasmic reticulum stress, causing morphological changes similar to those seen in multiple sclerosis. This finding indicates that senolytic interventions carry neurological risks that warrant careful evaluation before clinical deployment.
T Cell Immunosenescence in Inflammatory Skin Diseases: Pathogenesis and Therapeutic Targets
Aging T cells develop senescence characteristics that drive chronic inflammatory skin diseases through dysregulated signaling pathways and secretion of pro-inflammatory factors. Targeting senescent T cells or their signaling cascades offers a mechanism-based approach to achieving sustained remission in conditions like psoriasis and atopic dermatitis.
Rubedo: the senolytic alchemist of aging biology
Rubedo Life Sciences has advanced RLS-1496, a first-in-class GPX4 modulator senolytic, through Phase 1 human trials based on the company's ALEMBIC AI platform for identifying senescent cell vulnerabilities. This represents a shift from repurposed compounds toward precision-targeted senolytics designed to eliminate dysfunctional cells while sparing healthy tissue.
Two Polyunsaturated Lipids Demonstrate Senolytic Activity
Two conjugated polyunsaturated fatty acids, α-eleostearic acid and its methyl ester, demonstrated senolytic activity in cell cultures and mouse models across multiple tissues without systemic toxicity. The structural features of these compounds—particularly conjugation patterns and double-bond configuration—correlate with their ability to eliminate senescent cells, which accumulate with age and drive inflammatory cascades linked to chronic disease.
Epigenetic reprogramming reverses aging at cellular level
Epigenetic reprogramming represents a shift from static aging theories to a dynamic model where gene expression patterns—not DNA sequence itself—drive aging processes and can be therapeutically reversed. This reframes longevity interventions from inevitable decline management to targeted restoration of youthful cellular states.
Plasma Proteomic Profiling of Young and Older Adults Identifies Candidate Biomarkers of Biological Aging at the Intersection of Age and Disease
Proteomic analysis identified 311 plasma proteins whose expression patterns correlate with both chronological age and disease burden in older adults, representing candidate biomarkers of biological aging. These proteins suggest shared regulatory pathways between aging and chronic disease progression and may enable risk stratification and intervention monitoring.
New COSRX peptide serum taps growing skin longevity market
COSRX's Blue Peptide Bakuchiol serum addresses emerging consumer demand for skin resilience and long-term health rather than antiaging reversal, specifically acknowledging how body composition changes—including from GLP-1 medications—affect facial firmness and elasticity. The product democratizes peptide-based skincare by making copper tripeptide-1 accessible at mid-market price points rather than luxury positioning.
Telomere Restoration in Blood Cells Without Adverse Effects
Elixirgen is advancing two distinct therapeutic approaches for rare diseases: EXG-7001, a locally administered dystrophin mRNA for Duchenne muscular dystrophy, and EXG-34217, which uses engineered stem cells to achieve sustained telomere elongation in patients with telomere biology disorders. Early Phase 1/2 data demonstrates telomere lengthening without adverse events over 24 months, establishing proof of concept for a mutation-independent intervention in a class of diseases where cellular aging accelerates prematurely.
The ‘rising tide’ of mitochondrial therapies in longevity
Mitochondrial dysfunction is increasingly recognized as a central mechanism underlying age-related disease, not merely a feature of rare genetic conditions. The FDA approval of elamipretide (Forzinity) for Barth syndrome represents the first regulatory validation of mitochondria-targeted therapeutics, positioning this class of drugs as potential interventions for common age-related conditions including neurodegeneration and cardiac disease.
Senotype classification reframes cellular aging as adaptive or pathological
Senescent cells—those that have stopped dividing—exhibit distinct molecular profiles and functional outcomes depending on their origin and microenvironment. This classification framework clarifies why some senescent states support tissue repair while others drive chronic inflammation and age-related disease, fundamentally shifting how we interpret cellular aging.
Plasma Proteome Profiling of Centenarian Across Switzerland Reveals Key Youth‐Associated Proteins
Plasma proteomics of Swiss centenarians identified 37 proteins maintaining a younger profile despite advanced age, with pathways implicating immune regulation, metabolic enzyme function, and extracellular matrix stability. These findings establish reproducible molecular signatures of healthy longevity across independent cohorts and suggest specific protein targets for aging intervention.
Senescent Cell Distribution Across Tissues Enables Targeted Aging Intervention
Senescent cells accumulate across tissues with age and vary significantly by organ type and species, revealing tissue-specific patterns of cellular aging. This spatiotemporal map establishes a foundation for understanding which senescent populations drive age-related decline and represent therapeutic targets for longevity interventions.
‘Age reversal is the only viable path for effective therapy’
Telocyte's founder argues that effective longevity intervention requires reversing aging at the cellular level rather than managing age-related diseases incrementally. The company is preparing a telomerase gene therapy trial in dogs, with the thesis that aging results from failed maintenance systems that can be reset rather than from inevitable biological decline.
Targeting Hyperoxia‐Induced Cellular Senescence in Developing Human Airway Cells: Senomorphics Versus Senolytics Versus Antioxidants
Moderate hyperoxia induces cellular senescence in developing airway tissue, with lasting consequences for lung function. Three mechanistically distinct interventions—Fucoidan, Dasatinib plus Quercetin, and MitoQ—each mitigate senescence through different pathways, offering potential strategies to prevent hyperoxia-related lung disease in premature infants.
Liver Growth Hormone Signaling Loss Accelerates Aging in Mice
Deleting the growth hormone receptor specifically in hepatocytes shortened lifespan in mice and produced accelerated aging features including cellular senescence, cognitive decline, impaired bone mineralization, and heightened inflammatory tone. Loss of hepatic GHR signaling reduced STAT5b phosphorylation and increased nuclear PPARγ activity, driving Pdk4 and Cd36 transcription, mitochondrial damage, and fatty liver; pharmacological PDK4 inhibition reversed much of the damage. The result distinguishes tissue-specific growth hormone signaling from systemic GH reduction, which has been associated with longer lifespan.
Regenerative Platforms Outprice Drug Assets at Renewal Stage
Analysis of longevity biotech asset data indicates that regenerative platforms, validated once at the mechanism level, can be directed at multiple indications and regulatory pathways simultaneously, and that at the renewal stage they exceed drug-like assets in both aggregate capital ($18bn across 324 assets) and value per asset (~$56m vs ~$41m). MuseCell Innovations illustrates the model with Muse cells that home to damaged tissue via the S1P receptor, reaching roughly 15% of a lesion compared with under 1% for standard mesenchymal stem cells. The advantage is specific rather than universal: drug-like assets still dominate treatment-stage activity, prevention remains under 5% of the market, and most regenerative pipelines sit at Phase 1 or 2.
Biotechs race to turn aging science into cell-based therapies
Multiple biotech companies are developing cell-based therapies targeting aging as an underlying condition rather than treating age-related diseases individually. The longevity biotech market is projected to grow from $9.86 billion in 2025 to $29.7 billion by 2034, driven by approaches using encapsulated cells, gene therapy, and stem cell platforms.
A Robust Senescence Response Helps Wounds Heal
Younger mice demonstrate faster wound healing due to a more robust senescent cell response, while the accumulation of senescent cells with age paradoxically impairs regeneration. This reveals a temporal window in which senescent cell activation supports tissue repair before becoming detrimental.